Approaching Frontline Therapy in HER2-Mutant NSCLC

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss current approaches to frontline therapy in HER2-mutant non–small cell lung cancer. Dietrich reviews the ongoing role of chemotherapy with or without immunotherapy, particularly in the absence of upfront targeted options. Leal highlights considerations for deferring HER2-directed therapies to later lines and how these decisions are framed in clinical discussions with patients.